OCULAR IMMUNOLOGY AND UVEITIS FOUNDATION
EIN: 20-1891037Weston, MAZIP: 02493
H41 - Medical Research501(c)(3)
Mission
THE OCULAR IMMUNOLOGY AND UVEITIS FOUNDATION IS DEDICATED TO IMPROVING THE DIAGNOSIS AND TREATMENT AND FINDING THE CAUSES AND CURES OF UVEITIS AND OTHER OCULAR INFLAMMATORY DISEASES, INCREASE AWARENESS OF UVEITIS AMOUNG HEALTH PROFESSIONALS AND THE PUBLIC, AND SUPPORT INDIVIDUALS AND FAMILIES AFFECTED BY THE DISEASE.
Financials
| Year | Revenue | Expenses | Assets |
|---|---|---|---|
| 2024 | $1.6M | $0 | $3M |
| 2023 | $1.6M | $0 | $2.2M |
| 2022 | $734k | $0 | $1.1M |
Compensation
2024
2023
2022
Similar Organizations
TEAR FILM OCULAR SURFACE SOCIETY INC
$1.4M revenueBoston, MA
Same sector (H41)Similar revenue ($1.4M vs $1.6M)Same state (Massachusetts)
BEAT CHILDHOOD CANCER FOUNDATION INC
$1.6M revenueBraintree, MA
Similar sector (H)Very similar revenue ($1.6M vs $1.6M)Same state (Massachusetts)
THE ALBERT F EGAN JR & DOROTHY H
$1.5M revenueNantucket, MA
Similar sector (H)Very similar revenue ($1.5M vs $1.6M)Same state (Massachusetts)
BEDFORD VA RESEARCH CORPORATION
$1.4M revenueBedford, MA
Similar sector (H)Very similar revenue ($1.4M vs $1.6M)Same state (Massachusetts)
Human Proteome Organization - HUPO
$1.5M revenueNewton, MA
Similar sector (H)Very similar revenue ($1.5M vs $1.6M)Same state (Massachusetts)
ONE MISSION INC
$1.5M revenueNewton, MA
Similar sector (H)Very similar revenue ($1.5M vs $1.6M)Same state (Massachusetts)
AMERICAN ACADEMY OF PAIN MEDICINE
$1.4M revenueNorth Reading, MA
Similar sector (H)Similar revenue ($1.4M vs $1.6M)Same state (Massachusetts)
THE SUMAIRA FOUNDATION INC
$1.8M revenueSomerville, MA
Similar sector (H)Similar revenue ($1.8M vs $1.6M)Same state (Massachusetts)
CORPORATION FOR ADVANCEMENT OF MEDICAL
$1.3M revenueBoston, MA
Similar sector (H)Similar revenue ($1.3M vs $1.6M)Same state (Massachusetts)
THE RICBAC FOUNDATION
$1.9M revenueNewtonville, MA
Similar sector (H)Similar revenue ($1.9M vs $1.6M)Same state (Massachusetts)
Data from IRS Form 990 filings (2022-2024).